Reported 16,275 shares, up 5,799 (55.4%) from the prior quarter.
Reported value 221.3%; share count 55.4% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 141000 |
| 2022-03-31 | 160000 |
| 2022-06-30 | 88000 |
| 2022-09-30 | 142000 |
| 2022-12-31 | 131154 |
| 2023-03-31 | 81294 |
| 2023-06-30 | 261214 |
| 2023-09-30 | 231343 |
| 2023-12-31 | 258492 |
| 2024-03-31 | 852224 |
| 2024-06-30 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q2 2024 | Reduced | 0 | -19,764 (-100.0%) | 0 | $0 | 2024-08-13 | |
| Q1 2024 | Added | 19,764 | +2,957 (17.6%) | < 0.01% | $852,224 | 2024-05-13 | |
| Q4 2023 | Reduced | 16,807 | -67 (-0.4%) | < 0.01% | $258,492 | 2024-02-13 | |
| Q3 2023 | Added | 16,874 | +599 (3.7%) | < 0.01% | $231,343 | 2023-11-13 | |
| Q2 2023 | Added | 16,275 | +5,799 (55.4%) | < 0.01% | $261,214 | 2023-08-04 | |
| Q1 2023 | Added | 10,476 | +3,698 (54.6%) | < 0.01% | $81,294 | 2023-05-12 | |
| Q4 2022 | Added | 6,778 | +127 (1.9%) | < 0.01% | $131,154 | 2023-02-10 | |
| Q3 2022 | Added | 6,651 | +163 (2.5%) | < 0.01% | $142,000 | 2022-11-14 | |
| Q2 2022 | Reduced | 6,488 | -306 (-4.5%) | < 0.01% | $88,000 | 2022-08-12 | |
| Q1 2022 | Added | 6,794 | +1,535 (29.2%) | < 0.01% | $160,000 | 2022-05-13 | |
| Q4 2021 | Added | 5,259 | +1,392 (36.0%) | < 0.01% | $141,000 | 2022-02-11 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
91 managers reported VERA THERAPEUTICS INC for Q2 2023.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| FMR LLC | Added | 6,535,560 | +739,301 | < 0.01% | $104,895,739 | 9 qtrs |
| COMMODORE CAPITAL LP | Added | 5,450,000 | +2,625,971 | 9.83% | $87,472,500 | 2 qtrs |
| Sofinnova Investments Inc | Unchanged | 3,467,156 | 0 | 3.64% | $55,647,854 | 9 qtrs |
| Kynam Capital Management LP | Reduced | 3,000,000 | -372,428 | 6.62% | $48,150,000 | 7 qtrs |
| Carlyle Group Inc | Reduced | 2,416,837 | -543,394 | 1.38% | $38,766,065 | 2 qtrs |
| BlackRock Inc | Added | 2,170,134 | +759,864 | < 0.01% | $34,830,651 | 9 qtrs |
| ORBIMED ADVISORS LLC | Added | 1,756,800 | +394,400 | 0.52% | $28,196,640 | 2 qtrs |
| Woodline Partners LP | Added | 1,753,690 | +972 | 0.33% | $28,146,725 | 4 qtrs |
| Eversept Partners LP | Reduced | 1,740,951 | -47,578 | 2.34% | $27,942,264 | 4 qtrs |
| VANGUARD GROUP INC | Added | 1,440,265 | +45,414 | < 0.01% | $23,116,253 | 9 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2023
- Filed
- August 04, 2023
- Filing type
- 13F-HR
- Position type
- CL A
Voting authority reported
- Sole
- 16,275
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.